Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Prostate Cancer Clinical Trial

Official title:

A Pilot, Feasibility Study of Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06172283
• Other study ID #: STUDY00007635
• Status: Recruiting
• Phase: N/A
• Start date: December 5, 2023
• Est. completion date: December 31, 2028

Study information

• Verified date: December 2023
• Source: State University of New York at Buffalo
• Contact: Roberto Pili, MD
• Phone: 716-881-8918
• Email: rpili[@]buffalo.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a a pilot study to assess the feasibility of intermittent caloric restriction (plus a plant-enriched diet optionally) in prostate cancer patients receiving androgen deprivation therapy. Study feasibility measures will include enrollment rate, drop-out rate and compliance with diet measured by self-reports.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2028
• Est. primary completion date: January 1, 2027
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• In order to be eligible for participation in this trial, the subject must:

• Be willing and able to provide written informed consent for the trial.

• Be male at birth and least 18 years of age on day of signing informed consent.

• Have measurable prostate cancer disease and be eligible for androgen deprivation therapy.

• Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.

• Demonstrate adequate organ function (all screening labs should be performed within 10 days of treatment initiation).

• Subjects have archival tumor tissue available or are willing to undergo a baseline biopsy prior to treatment.

• Subjects must have a life expectancy of at least 6 months.

Exclusion Criteria:

• Has an ECOG performance of 2 or higher.

• Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the beginning of the treatment.

• Has a known additional malignancy that is progressing or requires active treatment.

• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

• Has a known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT/MRI imaging

• Has any other medical intervention or condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives.

• Is not willing and able to provide written informed consent for the trial.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Other:
• Intermittent Fasting
Dietary intervention

Locations

Country	Name	City	State
United States	University at Buffalo/Great Lakes Cancer Center	Buffalo	New York

Sponsors (1)

Lead Sponsor	Collaborator
State University of New York at Buffalo

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Enrollment rate	Feasibility of intermittent fasting (with the option of a plant-enriched diet) in prostate cancer patients receiving androgen deprivation therapy	3 years
Primary	Drop-out rate	Feasibility of intermittent fasting (with the option of a plant-enriched diet) in prostate cancer patients receiving androgen deprivation therapy	3 years
Secondary	Number of patients who achieve either partial or complete response by RECIST criteria on tumor imaging.	Clinical efficacy of the combination of intermittent fasting with or without a plant-enriched diet plus androgen deprivation therapy	3 years
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.	Safety, tolerability and reduction of common toxicities of the combination of intermittent fasting and the option of a plant-enriched diet intervention as compared to historical data.	3 years